Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Is the pharmaceutical industry improving with regard to access to essential medicines

Writing in The Lancet Global Health, Professor Hans Hogerzeil and members of the Index Research Team set out the findings of the first longitudinal analysis based on the Access to Medicine Index. Hans V. Hogerzeil currently chairs the Expert Review Committee for the Access to Medicine Index.

Date

31 January 2014

Direct links

Read the full article

Read the article

Despite progress in many countries, about a third of the world’s population does not have regular access to essential medicines.  Since 2008, the Access to Medicine Index (the Index) has ranked the 20 largest research-based pharmaceutical companies according to their efforts in making relevant products more available, affordable, and accessible in developing countries.

The 2012 Index ranking is based on companies’ commitments and actions to provide medicines, vaccines, and diagnostic tests in 103 low-income and middle-income countries, focusing on 33 high-burden communicable, non-communicable, and neglected tropical diseases, as well as a range of maternal and neonatal disorders. Information received from companies is cross-checked with other sources, and peer reviewed by experts. The ranking is based on 101 indicators in seven technical areas: organisation and management of access programmes; conduct of relationships with policymakers, competitors, customers, and the public; research and development on relevant products; pricing policies and distribution; patent and licensing practices; capacity building in developing countries; and product donations and philanthropic activities. For each technical area four aspects are assessed: company commitment, transparency, performance, and innovation.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved